Agent Capital, an international life sciences investment firm, led a $38 million Series A funding round in Carbon Biosciences, a biotechnology company, with participation from Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, UTokyo and Camford Capital. “Identifying vectors that can effectively deliver therapeutics to target tissues, such as the lung, has been a major challenge in realizing the full potential of gene therapy. We believe that Carbon's proprietary platform can address this challenge by leveraging novel vectors from the broader parvovirus family to deliver optimal payloads to specific tissues. Carbon’s technology will enable a diversified pipeline with potential applications across the wide range of tissues impacted in many unaddressed diseases,” Geeta Vemuri, Agent Capital Managing Partner and Founder.